Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAccesswire • 08/11/22
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference CallAccesswire • 08/04/22
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast CancerAccesswire • 07/18/22
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a BetZacks Investment Research • 06/15/22
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 05/30/22
Celcuity Inc. (CELC) CEO Brian Sullivan on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference CallAccesswire • 05/09/22
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor ConferencesAccesswire • 04/05/22
Celcuity's (CELC) CEO Brian Sullivan on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business UpdatesAccesswire • 03/23/22
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference CallAccesswire • 03/16/22
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate UpdateAccesswire • 01/18/22
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer SymposiumAccesswire • 12/10/21
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process DevelopmentAccesswire • 11/29/21
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical TrialAccesswire • 11/15/21
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor ConferencesAccesswire • 11/09/21
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateAccesswire • 11/08/21
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference CallAccesswire • 10/29/21
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain MetastasesBusiness Wire • 10/18/21